Company News
-
Company News
Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine24 November,2025
Learn More
-
Company News
Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®12 September,2025
Learn More
-
Company News
Announces 2025 Interim Results29 August,2025
Learn More
-
Uni-Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches 肌顏態®: Pioneering Entry into the High-Growth Medical Aesthetics MarketCompany News
02 December,2024
-
Uni-Bio Science Announces 2024 Interim ResultsCompany News
28 August,2024
-
Synthetic Biotechnology | Pioneering a New Paradigm in "Quantitative Synthetic Biology" to Drive Rational Design of Complex Biological SystemsIndustry Trends
01 August,2024
-
Uni-Bio Science And Chongqing Minji Establish Strategic Partnership, Targeting Hundreds Of Billions Of Yuan of Medical Aesthetics Device MarketCompany News
10 July,2024
-
Uni-Bio Science Announces 2023 Annual ResultsCompany News
28 March,2024
-
Marketing application of Diquafosol Sodium eye drops has been officially accepted by the China National Medical Products Administration (NMPA)Company News
23 January,2024
-
As A Breakthrough Drug For The Expansive Osteoporosis Market, Bogutai® (Teriparatide Injection) Has Been Officially Approved By The China National Medical Products Administration (NMPA)Company News
22 January,2024
-
Uni-Bio Science 2023 Interim Results，Achieved Record High Profit of HK$39.4MCompany News
29 August,2023
-
Uni-Bio Science Announces 2022 Annual Results，Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D PartnershipsCompany News
28 March,2023
